40 ERIE STREET, CAMBRIDGE, MA
Market cap: $1.4B (2/12/2026)
Price: $11.87
Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN
Investor Presentation
Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy
Earnings Release
Other Events
Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)
Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy
Financial Results, Changes in Board, Management or Compensation
Q3
Q2
Q1
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Additional Proxy Materials
PRE 14A
Definitive Proxy Statement
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Confidential Treatment Order
Correspondence
Submission Upload